• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


H&T Presspart Low GWP Banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Aptar Pharma acquires rights to Pharmaxis’ Orbital DPI

Aptar Pharma announced that it has acquired worldwide rights to Pharmaxis’ high payload Orbital dry powder inhaler. In August 2021, the company said that it had acquired an option to purchase the rights to the Orbital DPI and that it had 12 months to decide whether or not to exercise that option. The Orbital inhaler can handle total doses up to 400 mg and was initially designed for delivery of Pharmaxis’ Bronchitol dry powder mannitol.

Aptar Pharma VP, Global Pulmonary Category, Howard Burnett said, “With this acquisition, Aptar Pharma is pleased to be building on our current expertise for the treatment of chronic conditions. As a recognized global leader in respiratory drug delivery devices and associated services, we now have a wider offering to meet our customer needs.”

Pharmaxis CEO Gary Phillips commented, “I am delighted that Aptar Pharma, who are one of the world’s foremost drug delivery device companies, have seen the potential in the Orbital technology. We look forward to them building on the technical evaluations carried out during the option period and delivering new product solutions that can benefit drug developers and patients. Today’s announcement is a further example of our strategy to generate non-dilutive cash from the mannitol respiratory business.”

Over the past few years, Aptar Pharma has been acquiring a wide range of OINDP companies and technologies. Earlier this year, the company launched an MDI sensor called HeroTracker Sense that was originally developed by Cohero Health, which was acquired by Aptar in 2020. In October 2021, Aptar announced that it would co-develop and promote i2c Pharmaceutical Services’ Respitab MDI technology. The previous year, the company acquired OINDP formulator Nanopharm and characterization specialist Gateway Analytical as well as device onboarding company Noble.

Read the Aptar Pharma press release.

Share

published on August 4, 2022

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Proveris_180x150a
    © 2025 OINDPnews